EUVIMEDEUVIMED entdecken
LeserbriefKommentar

On the interpretation of negative efficacy in the MUCOSA trial: is the role of eosinophils in refractory chronic cough truly dismissed?

Wenzhi Zhan, Jiaxing Xie iD, Wei Luo, Kefang Lai

European Respiratory Journal · 2026-05 · 67 (5) · 2502663

DOI: 10.1183/13993003.02663-2025 ↗

Kurz gefasst

Leserbrief in der Zeitschrift European Respiratory Journal, online erschienen am 07.05.2026. Verfasst von Wenzhi Zhan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Na…. Die Arbeit nennt 9 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, The First Affiliated Hospital…

ORCID-Profile: Jiaxing Xie

Zitieren

APA

Zhan, W., Xie, J., Luo, W., & Lai, K. (2026). On the interpretation of negative efficacy in the MUCOSA trial: is the role of eosinophils in refractory chronic cough truly dismissed?. European Respiratory Journal, 67(5), 2502663. https://doi.org/10.1183/13993003.02663-2025

Vancouver

Zhan W, Xie J, Luo W, Lai K. On the interpretation of negative efficacy in the MUCOSA trial: is the role of eosinophils in refractory chronic cough truly dismissed?. European Respiratory Journal. 2026;67(5):2502663. doi:10.1183/13993003.02663-2025

BibTeX
@article{Zhan2026,
  author = {Zhan, Wenzhi and Xie, Jiaxing and Luo, Wei and Lai, Kefang},
  title = {On the interpretation of negative efficacy in the MUCOSA trial: is the role of eosinophils in refractory chronic cough truly dismissed?},
  journal = {European Respiratory Journal},
  year = {2026},
  volume = {67},
  number = {5},
  pages = {2502663},
  doi = {10.1183/13993003.02663-2025}
}
Kostenlos starten →